Novocure GmbH

I'll research this company before writing the profile.

Company overview. Novocure GmbH is a wholly owned subsidiary of NovoCure Limited (NASDAQ: NVCR), a Jersey (Channel Islands)-incorporated, publicly traded oncology group. In its 2022 corporate disclosure statement, Novocure GmbH identified Novocure Luxembourg S.a.r.l. and NovoCure Limited as its parents. Novocure group entities named "Novocure GmbH" are registered in both Germany (Munich) and Switzerland, with the Swiss entity serving as EMEA headquarters and global operations center, per SEC Exhibit 21 filings and the company's German annual report. The group was founded in 2000 by Dr. Yoram Palti, is headquartered in Baar, Switzerland (moved from Root in January 2025), with U.S. headquarters in Portsmouth, New Hampshire and R&D in Haifa, Israel. Reported FY2025 net revenue was roughly $655M against a net loss of about $136M, with approximately 1,500–1,600 employees and a market capitalization in the $1.1–1.8B range (company press releases; stockanalysis.com).

Products / operations. This is an operating company. It develops and commercializes Tumor Treating Fields (TTFields) therapy — wearable, portable devices that deliver alternating electric fields to disrupt cancer-cell division. Commercial devices: Optune Gio (glioblastoma), Optune Lua (metastatic NSCLC and malignant pleural mesothelioma), and Optune Pax (locally advanced pancreatic cancer, FDA-approved February 2026). It also runs device-support and payer/insurance navigation programs.

Patent-litigation posture. An operating company asserting its own internally developed portfolio, not an NPE. The tracked data show 1 case as plaintiff and 0 as defendant. The single suit was filed in the Middle District of Florida (Tampa Division) rather than an NPE-favored venue.

Notable case. Novocure GmbH v. Fieldcure Co. Ltd. (8:22-cv-02535, M.D. Fla., filed Nov. 7, 2022) asserted U.S. Patents 7,136,699, 7,715,921, and 8,715,203 — covering apparatus for destroying dividing cells, in-vivo electrodes, and composite electrodes — against Korean-based FieldCure's competing TTFields device ahead of a planned Society for Neuro-Oncology conference exhibit. Novocure voluntarily dismissed the case without prejudice on Dec. 2, 2022.